U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07923071) titled 'A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment' on Oct. 28.
Brief Summary: The primary purpose of this study is to characterize the pharmacokinetic (PK) parameters of revumenib and its major metabolite, N-deethyl revumenib (M1) after a single dose of revumenib in participants with severe liver or kidney impairment or normal liver and kidney function.
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
Relapsed/Refractory (R/R) Hematologic Malignancies
Acute Leukemia
Refractory Leukemia
Relapsed Leukemia
Intervention:
DRUG: Revume...